Tanabe Pharma Corporation

This completed Phase 3 study tested a combined vaccine called BK1310 in 33 healthy infants. The vaccine aims to protect against diphtheria, tetanus, pertussis, polio, and Hib with a series of injections. Researchers measured antibody levels to see if the vaccine triggers a strong…

This study tested a new vaccine called MT-2301 to protect healthy infants against Haemophilus influenzae type b (Hib), a serious bacterial infection. Researchers compared it to the current standard vaccine, ActHIB, when given alongside other routine childhood shots. The goal was …

This study tested a booster dose of the DTaP vaccine (BK1301) in 446 adolescents aged 11-12 who had already received the standard childhood series. The goal was to confirm the vaccine boosts immunity against diphtheria, tetanus, and pertussis (whooping cough) safely. Results show…

This study tested a new vaccine called BK1310 in 267 healthy infants to see if it protects against tetanus, diphtheria, pertussis, polio, and bacterial meningitis as well as existing vaccines. Infants received three doses, and researchers measured their immune responses. The goal…

This study tested the drug edaravone (MCI-186) in 181 people with ALS, a progressive nerve disease. Participants received either edaravone or a placebo through IV infusions over 24 weeks. The goal was to see if edaravone could slow the decline in physical function. Results sugges…

This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…

This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…

This phase 2 study tested a new drug called teneligliptin (MP-513) in 324 Japanese adults with type 2 diabetes. Participants took one of three doses of the drug or a placebo daily for 12 weeks. The main goal was to see how well the drug lowered blood sugar levels (HbA1c) and to c…

This Phase 2 trial tested an experimental pill called TA-7284 in 383 adults with type 2 diabetes. The drug works by helping the kidneys remove extra sugar from the body through urine. Researchers compared four different doses of TA-7284 against a placebo to see how well it lowers…

This study tested a drug called TA-650 (also known as infliximab) in 14 children with moderate to severe Crohn's disease. The drug was given as an IV infusion to reduce inflammation and control symptoms. The goal was to see if it could lower disease activity scores and improve th…

This study tested a new drug called MP-424 (telaprevir) combined with two standard medications (peginterferon and ribavirin) in 108 adults with genotype 2 hepatitis C whose infection returned after previous treatment. The goal was to see if this triple therapy could clear the vir…

This study tested whether increasing the dose of infliximab (a drug that blocks inflammation) helps people with active rheumatoid arthritis who did not get enough relief from methotrexate alone. A total of 327 adults received three initial infusions of infliximab, then were given…

This completed study tested an experimental drug called MP-214 in 512 adults with schizophrenia who were having a flare-up of symptoms. Participants took either a placebo, a standard antipsychotic (risperidone), or one of three doses of MP-214 daily for six weeks. The main goal w…

This study tested the long-term safety and effectiveness of MP-214, a once-daily pill, in 125 people with chronic or elderly schizophrenia. Participants took a fixed dose for four weeks, then a flexible dose for the rest of the study. The goal was to see if MP-214 could help mana…

This phase 3 study tested an oral drug called MT-6548 (vadadustat) in 24 adults on hemodialysis in Japan who have anemia due to chronic kidney disease. The goal was to see if the drug can raise and keep hemoglobin levels in a healthy range. Participants took the pill and had thei…

This study tested a drug called teneligliptin in 254 Chinese adults with type 2 diabetes. Half received the drug and half received a placebo for 24 weeks. The main goal was to see if teneligliptin lowers blood sugar levels (HbA1c) better than a placebo. Researchers also checked f…

This study tested the long-term safety of a drug called MCI-196 (Colestilan) in 116 adults with stage 5 chronic kidney disease who are on dialysis and have high phosphorus levels. Participants took flexible doses of the drug for 52 weeks. The main goal was to see how many side ef…

This study tested whether adding teneligliptin to the standard diabetes drug pioglitazone improves blood sugar control in 204 Japanese adults with type 2 diabetes. Participants received either a placebo or teneligliptin for 12 weeks, followed by an open-label extension for up to …

This Phase 3 trial tested whether AST-120, a spherical carbon adsorbent taken as a powder, can slow the progression of chronic kidney disease. Over 1,000 adults with moderate to severe kidney disease received either AST-120 or a placebo alongside their usual care. The main goal w…

This Phase 3 trial tested MCI-196, a drug that binds phosphorus and lowers cholesterol, in 642 adults on dialysis with chronic kidney disease. Participants received either MCI-196 or a placebo for 12 weeks. The goal was to see if the drug could safely reduce both serum phosphorus…

This study tested an experimental drug called TA-7284 in 272 adults with type 2 diabetes. Participants took either a low dose, high dose, or a placebo pill daily for 24 weeks. The goal was to see if the drug safely lowers blood sugar levels (measured by A1C) compared to placebo.

This study tested a lower dose (0.6 mg/kg) of the clot-busting drug alteplase in 103 Japanese patients who had a stroke within the previous 3 hours. The goal was to see if this dose was both safe and effective for this population. Results focused on how many patients had little t…

This study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa-2b and ribavirin) in 189 adults with genotype 1 hepatitis C who had never been treated before. The main goal was to see if the virus could be cleared from the blood 2…

This study looked at a new drug called MP-214 in 38 adults with schizophrenia. The goal was to see how safe the drug is, how the body processes it, and whether it helps control symptoms. Participants took the drug for 12 weeks, and researchers monitored side effects and drug leve…

This study tested a once-daily combination of two diabetes drugs (Teneligliptin and Canagliflozin) in 153 Japanese adults with type 2 diabetes whose blood sugar was not well controlled on Teneligliptin alone. Participants took the combo pill for 52 weeks to see if it was safe and…

This study tested whether adding MP-435 to standard methotrexate treatment helps people with rheumatoid arthritis who did not get enough relief from methotrexate alone. Over 12 weeks, researchers measured improvements in joint pain, swelling, and daily function. The trial involve…

This study tested the drug canagliflozin in 308 Japanese adults with diabetic nephropathy (kidney damage from diabetes). The goal was to see if the drug could slow kidney function decline compared to a placebo. Participants took the drug or placebo for up to 104 weeks while conti…

This study tested a new drug called MT-6548 against a standard treatment (darbepoetin alfa) for anemia in people on dialysis for chronic kidney disease. About 323 participants in Japan received either the new drug or the standard one to see if it worked as well at keeping hemoglo…

This early-stage study tested an experimental drug called TA-7284 in 61 adults with type 2 diabetes. Participants took different doses (25 to 400 mg) or a placebo daily for 15 days. The goal was to check the drug's safety, how the body processes it, and its effects on blood sugar…

This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…

This phase 2 study tested MP-424 (Telaprevir) in 15 people with genotype 1b hepatitis C who had not been treated with interferon before. Participants took three 250 mg tablets every 8 hours for 24 weeks. The main goal was to see if the virus became undetectable 24 weeks after tre…

This phase 3 trial tested an oral drug called MT-6548 (vadadustat) against a standard injected drug (darbepoetin alfa) for anemia in people with chronic kidney disease who are not on dialysis. The study enrolled 304 participants in Japan to see if the oral drug is at least as goo…

This study tested whether adding canagliflozin, a diabetes pill, to insulin therapy helps people with type 2 diabetes control their blood sugar better. 146 adults who were already on a stable insulin dose took either canagliflozin or a placebo for 16 weeks. Researchers measured c…

This study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III) to see if it could slow the disease. Participants received either the drug or a placebo daily through an IV for 24 weeks. The main goal was to measure changes in daily function and safety,…

This study tested a drug called MCI-196 in 336 adults on dialysis with chronic kidney disease and high phosphorus levels. After a washout period, some patients received MCI-196 and others a placebo to see if the drug could safely lower phosphorus. The goal was to manage a common …

This early-phase study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa-2b and ribavirin) in 20 people with chronic hepatitis C genotype 1b. The main goal was to check the safety of the drug combination and measure how the dru…

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). Participants either had never been treated before or had previously received interferon-based therapy. The main…

This study tested a drug called TA-650 in 21 children with moderate to severe ulcerative colitis, a condition causing inflammation and sores in the colon. The goal was to see if the drug could reduce disease activity and improve symptoms. Children received the drug by infusion at…

This study looked at how well the drug argatroban works in 20 adults with a condition called heparin-induced thrombocytopenia Type II, where the blood thinner heparin causes low platelets and raises clot risk. Participants received argatroban to prevent new or worsening blood clo…

This study tested three doses of a blood thinner called argatroban, given with clopidogrel and aspirin, in 140 people having a heart artery procedure (PCI) for stable coronary artery disease or unstable angina. The goal was to see how well argatroban prevents blood clots and caus…

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 109 people with genotype 1 hepatitis C whose virus returned after previous treatment. The goal was to see if this combination could make the virus undetectab…

This study looked at whether a higher dose (10 mg/kg) of the drug infliximab (TA-650) could help people with Crohn's disease who were not getting enough benefit from the standard dose (5 mg/kg). The 39 participants received the higher dose every 8 weeks. The main goal was to see …

This study tested an experimental drug called MT-6548 in 42 people in Japan who have anemia due to chronic kidney disease and are on peritoneal dialysis. The goal was to see if the drug can safely raise and maintain healthy red blood cell levels. Participants either switched from…

This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease compared to a placebo over 24 weeks. The main measure was a scale of daily function. The trial did not show …

This study looked at whether adding the drug teneligliptin to insulin therapy helps control blood sugar better in people with type 2 diabetes. 148 Japanese adults with diabetes took part for up to 52 weeks. The main goal was to see if their HbA1c (a measure of long-term blood sug…

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 32 adults with genotype 1 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the blood 24 we…

This study tested whether AST-120, a charcoal-like pill, can slow kidney disease in 1015 adults with moderate to severe chronic kidney disease. Participants took AST-120 or a placebo alongside their usual care. The goal was to see if the drug could delay the need for dialysis, a …

This study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking other antipsychotic medications. The main goal was to see how many people had side effects. The study was completed and hel…

This study tested a combination of two diabetes medications, teneligliptin and canagliflozin, taken once daily for 24 weeks. It included 138 Japanese adults with type 2 diabetes whose blood sugar was not well controlled on teneligliptin alone. The goal was to see if adding canagl…

This study tested whether taking a higher dose of ursodeoxycholic acid (UDCA), a bile acid medication, could better control liver damage in people with chronic hepatitis C. About 596 adults in Japan took either 150 mg, 600 mg, or 900 mg of UDCA daily for 24 weeks. The main goal w…

This study tested a drug called TA-650 (similar to infliximab) in 18 people with Behcet's disease who had severe symptoms like brain or eye problems. The drug was given as an IV infusion at weeks 0, 2, and 6, then every 8 weeks up to week 46. The goal was to see if symptoms disap…

This study tested four different doses of an experimental drug called MP-513 in 448 adults with type 2 diabetes who were already taking metformin. The goal was to see if adding MP-513 could lower blood sugar more effectively and safely over 24 weeks, with an optional extension up…

This study compared two medications, edaravone and sodium ozagrel, for treating acute ischemic stroke. Researchers wanted to see which drug helped more people recover with little or no disability three months after treatment. The study included 401 adults who started treatment wi…

This study tested a new diabetes medicine called MP-513 (Teneligliptin) in 203 Japanese adults with type 2 diabetes. The goal was to see if the drug safely lowers blood sugar levels over 12 weeks. Participants took either the drug or a placebo pill, and researchers measured chang…

This study looked at the long-term safety and how well the drug MP-214 works for people with schizophrenia. It included 254 patients who had already completed an earlier study. The main goal was to track any side effects over time.

This study tested the long-term safety and blood sugar control of the drug MP-513 (Teneligliptin) in 240 Japanese adults with type 2 diabetes. Some participants took MP-513 alone, while others took it together with another diabetes medicine called glimepiride. The study lasted 52…

This study tested a clot-dissolving medicine called alteplase in 58 people who had a stroke caused by a blocked artery. The goal was to see how well it reopened blocked brain arteries and improved patients' ability to function three months later. The results were compared to exis…

This study tested whether adding teneligliptin to canagliflozin helps Japanese adults with type 2 diabetes who still have high blood sugar despite taking canagliflozin alone. Over 24 weeks, 154 participants took both drugs once daily. The main goal was to see if the combination l…

This study tested a new drug called MP-513 in 99 Japanese adults with type 2 diabetes. The goal was to see how well it controls blood sugar levels over 4 weeks. Participants took the drug and had their blood sugar measured after meals and throughout the day.

This study tested a drug called MCI-186 in 206 people with ALS, a disease that weakens muscles over time. The goal was to see if the drug could slow the decline in physical function over 24 weeks compared to a placebo. Participants received daily intravenous doses, and researcher…

This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in adults with type 2 diabetes. A total of 139 people who had completed a previous 16-week study took part. Researchers tracked side effects, blood sugar control, and weight cha…

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the med…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their phosphorus and cholesterol. The goal was to help contr…

This study tested the long-term safety of MP-513 (Teneligliptin) in 462 Japanese adults with type 2 diabetes. Participants took the drug alone or with other oral diabetes medicines for 52 weeks. The main goal was to track side effects, and researchers also measured blood sugar co…

This study tested a new daily pill called MP-214 in 34 adults with schizophrenia. The goal was to check safety, how the drug moves in the body, and if it helps control symptoms. Participants took a low, medium, or high dose for 14 days. This is an early-stage study, so more resea…

This study looked at whether adding canagliflozin to an existing GLP-1 medication is safe and helpful for people with type 2 diabetes. 71 adults took the combination for 52 weeks. Researchers tracked side effects, blood sugar levels, weight, and blood pressure. The goal was to se…

This study tested a new medication, TA-7284, in 1,299 adults with type 2 diabetes over 52 weeks. The goal was to see if the drug is safe and helps control blood sugar when used alone or with other diabetes medicines. Results focused on side effects, blood sugar levels, and weight…

This study tested whether adding the drug MP-513 (Teneligliptin) to standard sulfonylurea treatment helps control blood sugar in people with type 2 diabetes. About 194 Japanese adults aged 20-75 took part, and the main goal was to see changes in HbA1c (a long-term blood sugar mea…

This study tested an experimental drug, MCI-196, in 183 people with type 2 diabetes to see if it could help control blood sugar and improve cholesterol levels. Participants took the drug or a placebo for 12 weeks. The goal was to measure changes in blood glucose and HbA1c, a key …

This study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard IVIG treatment. The goal was to see if TA-650 could reduce fever and prevent heart artery damage better than a control treatment. The trial is complete, and resu…

This study tested a new drug called MP-424 combined with two standard hepatitis C medications (PEG-IFN Alfa-2a and RBV) in 54 adults with genotype 1 hepatitis C who either had never been treated or had relapsed after prior treatment. The main goal was to see if the virus was stil…

This study tested a drug called MCI-196 in 245 adults on dialysis who have high phosphate levels, a common problem in advanced kidney disease. After a 4-week washout and 12-week dose adjustment, patients were randomly assigned to continue MCI-196 or switch to a placebo for 4 week…

This study tested whether TAU-284 (bepotastine besilate) tablets can safely relieve nasal allergy symptoms like sneezing, runny nose, and congestion in children aged 7 to 15 with perennial allergic rhinitis. Over 470 children took either the drug or a placebo twice daily for two …

This study tested a once-daily drug called MT-5199 in 256 adults with tardive dyskinesia, a condition causing uncontrollable movements. The goal was to see if the drug could reduce these movements safely. Participants had mental health conditions like schizophrenia or bipolar dis…

This study tested a new medicine called MT-5547 to see if it can reduce moderate to severe pain from osteoarthritis of the knee or hip. About 626 Japanese adults aged 40 to 85 took part. The main goal was to measure pain changes over 16 weeks using a standard pain scale.

This study tested a new medicine called TAU-284 to see if it could reduce itching in children with eczema (atopic dermatitis). About 300 children aged 7 to 15 took part. The goal was to compare TAU-284 to an existing medicine, ketotifen, to see if it worked just as well.

This study tested a medicine called TAU-284 in 490 children aged 7 to 15 who have year-round nasal allergies. The goal was to see if it reduces sneezing, runny nose, and congestion better than a placebo. The trial was completed and focused on symptom relief, not a cure.

This study tested the long-term safety and effectiveness of TAU-284 (bepotastine besilate) in 58 children aged 7 to 15 with perennial allergic rhinitis (year-round nasal allergies). Over 12 weeks, researchers tracked side effects and changes in sneezing, runny nose, and congestio…

This early-stage study tested a new drug called MT-8554 in 24 women who have frequent hot flashes due to menopause or breast cancer treatment. The main goal was to check the drug's safety and how the body processes it. Researchers also looked at whether it could reduce the number…

This study tested an experimental drug called MT-8554 to see if it could reduce pain in people with diabetic peripheral neuropathy, a common complication of diabetes that causes nerve pain. The trial involved 156 adults who received either the drug or a placebo for 12 weeks. The …

This study tested an experimental drug called MT-8554 in 61 adults with painful diabetic peripheral neuropathy, a common complication of diabetes causing nerve pain. The goal was to see if the drug could safely reduce pain compared to a placebo. Participants took the drug or plac…

This early-stage study tested a single dose of MT-8554, a new drug being developed for pain, in 20 healthy men. Researchers measured how the drug affects the body's response to a cold-induced pain test and checked for safety. The goal was to gather initial data, not to treat any …

This early-phase trial tested the safety and how the body processes the drug MT-7117 (dersimelagon) in 40 healthy Chinese adults aged 18 to 55. Participants received either the drug or a placebo, and researchers measured drug levels in the blood and monitored for side effects. Th…

This study looked at how a diabetes drug called TA-7284 works in people with type 2 diabetes who also have moderate kidney problems. 24 adults took a single dose of the drug to see how it moved through their bodies and affected blood sugar. The goal was to understand how kidney f…

This study looked at how the drug edaravone enters the body when given as a liquid by mouth or through a nasogastric tube (a thin tube that goes through the nose to the stomach). It involved 36 healthy Japanese adults aged 20 to 45. The main goal was to measure drug levels in the…

This completed Phase 1 trial looked at how colestilan, a drug for high phosphate levels in kidney disease, affects the body's processing of candesartan, a blood pressure medication. Eighteen healthy men took candesartan alone or with colestilan at different times. The goal was to…

This completed Phase 1 study looked at how the drug MCI-186 (Edaravone) is processed in the body of people with severe liver impairment compared to healthy individuals. Twelve participants received a single intravenous dose. The goal was to measure drug levels and safety, not to …

This study tested whether an oral suspension of edaravone is processed by the body the same way as the IV form. Forty-two healthy Japanese adults received a single dose of each version. The goal was to see if the oral form could be a suitable alternative to the injection.

This study looked at how the drug MCI-186 (also called edaravone) behaves in people with mild or moderate liver impairment compared to healthy individuals. Twenty-two adults received a single dose of the drug intravenously. Researchers measured drug levels in the blood to see if …

This early-stage study tested the safety and how the body handles a new drug called MT-8554 in 135 healthy adults. Participants were monitored for side effects and drug levels in the blood. The goal was to gather safety information, not to treat any disease.

This early-stage study looked at how a single dose of oral edaravone moves through the bodies of 9 Japanese adults with ALS. The main goal was to measure drug levels in the blood and urine, not to test if it helps symptoms. Researchers also tracked any side effects. The study is …

This study looked at how eating different types of meals affects the way the body absorbs oral edaravone, a medication used for ALS. Sixteen healthy Japanese adults took the drug under five different dietary conditions, including fasting. The goal was to understand how food chang…

This study looked at how the drug MCI-186 is handled by the body in people with mild or moderate kidney impairment compared to those with normal kidneys. Thirty adults received a single dose of the drug, and researchers measured its levels in the blood. The goal was to understand…

This early-stage study looked at how the body handles a single dose of oral edaravone in 6 Japanese ALS patients who have a feeding tube (gastrostomy). The goal was to measure drug levels in the blood and urine, not to test if it works. No treatment benefit was evaluated.

This study looked at how a new drug called MT-8554 changes the way the body processes two common cholesterol-lowering medicines, simvastatin and rosuvastatin. Twenty-eight healthy men took the statins alone and then with MT-8554 to see if their blood levels changed. The goal was …

This early-stage study tested an oral form of edaravone in 74 healthy adult men to see how the body processes the drug and whether it is safe. Participants took single or multiple doses of the drug as a solution or suspension. The goal was to gather information on safety and drug…

This study looked at how iron supplements change the way the body handles a drug called MT-6548. It involved 61 healthy Japanese men and measured drug levels in the blood. The goal was to gather safety and drug interaction data, not to treat any disease.

This study tested whether MCI-186, an experimental drug, changes the heart's electrical activity (QT interval) in 27 healthy adult men. Participants received a low dose, a high dose, and a placebo on separate days. The goal was to see if the drug could cause dangerous heart rhyth…

This study looked at how an oral form of edaravone interacts with three other drugs (rosuvastatin, sildenafil, furosemide) in healthy adult males. It also compared how the drug works in Japanese and Caucasian men. The goal was to gather safety and drug-level data, not to treat an…